Bengaluru-based manufacturer of hard capsule shells (gelatin and vegetarian/HPMC) for pharma and nutraceutical companies, now expanding into steroidal API manufacturing via subsidiary Natural Biogenex.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 6 | 6 | 7 | 9 | 9 | 10 | 10 | 10 |
| Reserves | 49 | 56 | 76 | 114 | 194 | 176 | 235 | 165 |
| Borrowings | 6 | 10 | 53 | 97 | 109 | 152 | 112 | 162 |
| Other Liabilities | 14 | 27 | 29 | 70 | 64 | 81 | 62 | 87 |
| Total Liabilities | 76 | 99 | 165 | 290 | 377 | 419 | 420 | 424 |
| AssetsFixed Assets | 24 | 38 | 66 | 97 | 103 | 284 | 281 | 274 |
| CWIP | 2 | 7 | 20 | 88 | 144 | 0 | 1 | 4 |
| Investments | 6 | 0 | 0 | 0 | 3 | 3 | 3 | 3 |
| Other Assets | 45 | 54 | 79 | 105 | 127 | 133 | 135 | 143 |
| Total Assets | 76 | 99 | 165 | 290 | 377 | 419 | 420 | 424 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 2 | 7 | 13 | -1 | 17 | -8 | 27 | 11 |
| Cash from Investing | -7 | -6 | -16 | -46 | -105 | -73 | -44 | -11 |
| Cash from Financing | 4 | -1 | 3 | 48 | 87 | 82 | 16 | -1 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -5 | 2 | -11 | -47 | -88 | -79 | -18 | -1 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
NATCAPSUQ · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.